John Marquardt focuses his practice on biotechnology and pharmaceutical patents. He has extensive experience in biochemistry and molecular pharmacology, including experience working with multiple blockbuster drugs.
John helps clients achieve their goals through patent prosecution, due-diligence, and litigation. He has performed and managed complex and extensive electronic discovery. John also conducts pre-suit investigations and provides freedom to operate and validity opinions.
Drawing on over fourteen years of experience in scientific research at MIT, Harvard University, and the NIH, John’s laboratory experience includes work in genetic and protein engineering, macromolecular structure determination using nuclear magnetic resonance (NMR) spectroscopy and x-Ray crystallography, and modern drug-design.
John works on subject matter including traditional small-molecule drugs, gene therapies, protein therapeutics, monoclonal antibody therapies, diagnostic methods, and devices. His extensive experience in biochemistry and molecular pharmacology includes methods in molecular and cellular biology, immunology, microbiology, biochemistry, genomics, computational biology, small molecule pharmaceuticals, and biopharmaceuticals.
John is a frequent commentator, speaker, and author on patent law, specifically in the area of biosimilars. He has also lectured on strategic considerations under the Biologics Price Competition and Innovation Act (BPCIA).
While in law school, John served as an intern to the Honorable Randall R. Rader, in the US Court of Appeals for the Federal Circuit.
John is based in Washington, DC.